Deleuran, Mette, et al. “Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents With Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use”. Acta Dermato-Venereologica, vol. 101, no. 7, July 2021, p. adv00504, doi:10.2340/00015555-3848.